Amrutanjan health care Limited has submitted its quarterly compliance certificate under SEBI (Depository Participants) Regulations for the quarter ended 31/03/2026. The filing was made on April 08, 2026, to both the National Stock Exchange of India Limited and BSE Limited, demonstrating the company's commitment to regulatory compliance.

Regulatory Compliance Details

The compliance certificate was submitted pursuant to Regulation 74(5) of the SEBI (Depository Participants) Regulation, 2018. The certificate was issued by Cameo Corporate Services Limited, which serves as the company's Registrar and Share Transfer Agents.

Certificate Confirmation

Cameo Corporate Services Limited confirmed that securities received from depository participants for dematerialisation during the quarter ended 31st March 2026 were properly processed. The registrar verified that all securities were confirmed to the depositories and that the securities comprised in the certificates have been listed on stock exchanges where the company's earlier issued securities are traded.

The certificate also confirms that security certificates received for dematerialisation were mutilated and cancelled after due verification by the depository participant. Additionally, the names of the depositories have been substituted in the register of members as the registered owner within the stipulated time limit under the captioned regulations.

Corporate Communication

The compliance filing was signed by Gagan Preet Singh, General Manager - Legal, Company Secretary & Compliance Officer of Amrutanjan Health Care Limited. The communication was addressed to both major stock exchanges where the company's shares are listed, ensuring comprehensive regulatory disclosure.

This quarterly compliance certificate submission reflects the company's ongoing adherence to SEBI regulations governing depository participants and securities dematerialisation processes.

Amrutanjan Health Care Limited has informed stock exchanges about receiving a tax demand order of Rs 24.28 lakh under the CGST/IGST Act 2017, as disclosed in a regulatory filing dated March 18, 2026.

Order Details and Authority

The order was issued by the Additional Commissioner of Central Excise & Customs (Appeals-II) on March 17, 2026, under sections 73 & 74 of the CGST Act 2017. The company has submitted the required details pursuant to Regulation 30 of SEBI Listing Regulations and SEBI Circular dated July 13, 2023.

Nature of Alleged Violations

The first appellate authority has passed an order for reversal of input tax credit on account of GSTR2A mismatch and questioned the eligibility of input tax credit for the financial years 2020-21 to 2021-22. The total tax demand amounts to Rs 24.28 lakh along with applicable interest and penalty.

Company's Response and Position

Amrutanjan Health Care has expressed disagreement with the order and stated it will take appropriate action for rectification or reversal. The company maintains that it availed input tax credit after fulfilling all conditions as per GST law provisions. Based on the merits of the case, the company plans to file an appeal against the order.

Financial Impact Assessment

According to the company's assessment, this order does not have any major financial implications on its operations. The management has indicated confidence in its position regarding the proper availment of input tax credit in compliance with GST regulations.

The disclosure was signed by Gagan Preet Singh, General Manager - Legal, Company Secretary & Compliance Officer, ensuring compliance with regulatory requirements under SEBI Listing Regulations.